ArticleResearch and practice in thrombosis and haemostasis2025
Protease-activated receptor 4 deficiency increases mortality, intracranial bleeding, and blood-brain barrier impairment following traumatic brain injury in mice.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PAR for the course - protease-activated receptor 4 protects the brain from hemorrhage.Research and practice in thrombosis and haemostasis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Protease-activated receptors (PARs), comprising PAR1 to PAR4, play a critical role in hemostasis and are considered potential therapeutic targets. Clinical trials have evaluated the safety and dosage of PAR4 antagonists, and a pathogenic role of PAR4 has been demonstrated in animal models of coagulopathies, including hemorrhagic brain injury. However, there is a lack of studies regarding the acute effects of PAR4 deficiency (PAR4 Objectives: To determine the role of PAR4 in cerebral hemostasis after TBI. Methods: Adult male PAR4 Results: PAR4 Conclusion: Our results demonstrate a crucial role for PAR4 in cerebral hemostasis following experimental TBI in mice and suggest that particular caution is warranted in the therapeutic management of PAR4-targeted treatment of coagulopathies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.